
-
Seres Therapeutics NasdaqGS:MCRB Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline programs include SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease; and SER-287 and SER-301, which are in clinical trials for the treatment of mild-to-moderate ulcerative colitis. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Location: 101 Cambridgepark Drive, Cambridge, MA, 02140, United States | Website: https://www.serestherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
92.26M
Cash
58.85M
Avg Qtr Burn
-21.62M
Short % of Float
12.41%
Insider Ownership
13.01%
Institutional Own.
35.23%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VOWST (SER-109) Details Bacterial infection, Clostridioides difficile infection | Approved Quarterly sales | |
SER-155 Details Graft-versus-host disease , Intestinal infection | Phase 1b Update | |
SER-287 Details Inflammatory bowel disease, Ulcerative colitis | Failed Discontinued | |
SER-401 Details Melanoma, Cancer | Failed Discontinued | |
SER-301 Details Inflammatory bowel disease, Ulcerative colitis | Failed Discontinued |